P H Y S I C I A N S ' A C A D E M Y ...
Rosuvastatin, Proprotein Convertase Subtilisin/Kexin Type 9 Concentrations, and LDL Cholesterol Response: the JUPITER Trial Z. Awan, N.G. Seidah, J.G.
Consumer behavior studies1 CONSUMER BEHAVIOR STUDIES STATISTICAL ISSUES Ralph B. D’Agostino, Sr. Boston University Harvard Clinical Research Institute.
Emerging Approaches To Improve LDL-C Reduction in Hypercholesterolemia
Emerging targets in HDL modification: Relevant data from development programs Prof. John Kastelein Academic Medical Centre Amsterdam, The Netherlands.
Goal Achievement after Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects (GAUSS): Results from a Randomized, Double-blind, Placebo- Controlled.
The concept of Diabetes & CV risk: A lifetime risk challenge
Emerging targets in HDL modification: Relevant data from development programs
Presenter Disclosure Information
